{"nctId":"NCT03780959","briefTitle":"Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)","startDateStruct":{"date":"1997-05-01","type":"ACTUAL"},"conditions":["Juvenile Rheumatoid Arthritis"],"count":69,"armGroups":[{"label":"Etanercept/Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Etanercept","Drug: Placebo"]},{"label":"Etanercept/Etanercept","type":"EXPERIMENTAL","interventionNames":["Drug: Etanercept"]}],"interventions":[{"name":"Etanercept","otherNames":["Enbrel","TNFR:Fc"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of JRA by the American College of Rheumatology (ACR) criteria.\n* Disease course must be polyarticular with disease duration long enough to have been given an adequate trial of non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose methotrexate at a dose of at least 10 mg/m²/week\n* Continuing active disease, defined as ≥ 5 swollen joints and ≥ 3 joints with limitation of motion accompanied by pain, tenderness or warmth.\n* Disease refractory to methotrexate or intolerant of methotrexate.\n* Have not received disease-modifying anti-rheumatic drugs (DMARDs) within 28 days prior to enrollment.\n* Have not received methotrexate within 14 days prior to dosing of study drug.\n\nExclusion Criteria:\n\n* Pregnant or nursing female\n* Functional class IV by ACR criteria\n* Unable to meet concomitant medication restrictions\n* Intraarticular corticosteroid injection within 4 weeks prior to enrollment\n* Clinically significant deviations from normal, defined as:\n\n  * thrombocytopenia; platelet count \\< 100,000/cmm\n  * leukopenia; total white cell count \\< 4000 cells/cmm\n  * neutropenia; neutrophils \\< 1000 cells/cmm\n  * hepatic transaminase levels \\> two times the upper limit of normal (ULN)\n  * serum bilirubin \\> 2 times ULN\n  * creatinine clearance \\< 90 mL/min/1.73 m² body surface area (BSA) and/or a glomerular filtration rate (GFR) \\< 90 mL/min/1.73 m² BSA.\n  * known human immunodeficiency virus (HIV), hepatitis B surface antigen positivity, or hepatitis C positivity.\n  * anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies or anti-cardiolipin antibodies present.\n* Previously received antibody to TNF, antibody to cluster of differentiation (CD)4, or diphtheria interleukin (IL)-2-fusion protein (DAB-IL-2)\n* Participated in a study of an investigational drug or biologic requiring informed consent within 3 months prior to study entry.\n* Any concurrent medical condition which would, in the investigator's opinion, compromise the patient's ability to tolerate the study drug or make the patient unable to cooperate with the protocol.\n* History of or current psychiatric illness that would interfere with ability to comply with protocol requirements or informed consent.\n* History or drug or alcohol abuse that would interfere with ability to comply with protocol requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Disease Flare in Part 2","description":"Disease flare was defined as a 30% or greater worsening in three of the six JRA Core Set Criteria and ≥ 30% improvement in one or less of the six JRA Core Set Criteria compared to day 90 and a minimum of two active joints (joints with swelling or limitation of movement plus pain and/or tenderness).\n\nThe JRA Core Set criteria consisted of:\n\n* Physician global assessment of disease severity assessed on a visual analog scale (VAS) from 0 (asymptomatic) to 10 (severe symptoms);\n* Patient/parent global assessment of overall well-being assesses on a VAS from 0 (asymptomatic) to 10 (severe symptoms);\n* Number of active joints;\n* Number of joints with limitation of motion (LOM) and with pain, tenderness, or both;\n* Childhood Health Assessment Questionnaire (CHAQ) disability domain;\n* Erythrocyte sedimentation rate (ESR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Flare in Part 2","description":"The time from day 90 to flare. Participants who withdrew without flare were censored at the time of withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"116.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":69},"commonTop":["Upper respiratory tract infection","Injection site erythema","Headache","Injection site swelling","Injection site pruritus"]}}}